Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes : a multicentre study
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag034 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Ángel Rodríguez-Villodres und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, Seville 41013, Spai…. Hauptthemen laut MEDLINE: Enterobacter cloacae, beta-Lactamases, Bacterial Proteins, Anti-Bacterial Agents. Die Arbeit nennt 21 Literaturangaben. Gefördert von: CIBERINFEC, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa.
Abstract (Originalsprache)
Background
Antimicrobial resistance among Enterobacter cloacae complex and Klebsiella aerogenes is a growing clinical challenge, often driven by AmpC β-lactamase hyperproduction. This phenotype limits therapeutic options to cefepime or carbapenems.
Objectives
To assess the in vitro activity of conventional β-lactams, such as cefepime, piperacillin/tazobactam or carbapenems, and new-generation agents, including ceftazidime/avibactam, cefepime/taniborbactam, imipenem/relebactam, meropenem/vaborbactam, and cefiderocol, against AmpC-hyperproducing E. cloacae complex and K. aerogenes.
Methods
A total of 314 clinical isolates (200 E. cloacae complex and 114 K. aerogenes) recovered between March and December 2024, from eight Spanish centres were tested by broth microdilution (EUCAST). AmpC hyperproduction was confirmed phenotypically and carbapenemase was screened phenotypically/molecularly. WGS was performed for (i) 84 E. cloacae complex isolates, and (ii) six isolates with reduced susceptibility to at least one novel agent.
Results
High resistance rates were observed for piperacillin/tazobactam (up to 82.4%) and cefepime (up to 20.5%), whereas carbapenems showed variable activity. New-generation agents exhibited excellent activity, with susceptibility rates ≥99% in both species. Resistance to at least one new agent was found in only six isolates. In the WGS-analysed E. cloacae complex subset, Enterobacter hormaechei predominated (75%) with high STs and blaACT allele diversity. In the six reduced-susceptibility isolates, no carbapenemase or explanatory acquired β-lactamase was found.
Conclusions
Our findings underscore the need to take this phenotype into account in clinical practice and confirm the limited activity of conventional β-lactams against AmpC-hyperproducing E. cloacae complex and K. aerogenes, and support the use of newer agents as effective alternatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, Seville 41013, Spain.
- Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Microbiology Service, University Hospital Marqués de Valdecilla-IDIVAL, Cantabria, Spain.
- Microbiology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
- Microbiology Service, University Hospital Clinico San Cecilio, Granada, Spain.
ORCID-Profile: Ángel Rodríguez-Villodres, Jaime Esteban, José Miguel Cisneros, José Antonio Lepe
Förderung
- CIBERINFEC
- Instituto de Salud Carlos III
- Subdirección General de Redes y Centros de Investigación Cooperativa
- Ministerio de Economía, Industria y Competitividad
- European Union
- Subprograma Juan Rodés
- Ministerio de Ciencia, Innovación y Universidades, Spain
- Clinical Investigator
Zitieren
APA
Rodríguez-Villodres, Á., Rodríguez-Lozano, J., Mir-Cros, A., Chueca, N., Rodríguez-Rodríguez, M., Fraile-Valcárcel, N., Puigsech-Boixeda, G., Fernández-Bermudo, C., Rodríguez-Pardo, D., Arjona-Torres, C., Cañada-García, J. E., García-Cobos, S., Gracia-Ahufinger, I., Ortega-Portas, C., Esteban, J., Soto, S. M., Cisneros, J. M., & Lepe, J. A. (2026). Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes : a multicentre study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag034
Vancouver
Rodríguez-Villodres Á, Rodríguez-Lozano J, Mir-Cros A, Chueca N, Rodríguez-Rodríguez M, Fraile-Valcárcel N, et al. Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes : a multicentre study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag034
BibTeX
@article{RodrguezVillodres2026,
author = {Rodríguez-Villodres, Ángel and Rodríguez-Lozano, Jesús and Mir-Cros, Alba and Chueca, Natalia and Rodríguez-Rodríguez, Marta and Fraile-Valcárcel, Nuria and Puigsech-Boixeda, Guillem and Fernández-Bermudo, Carmen and Rodríguez-Pardo, Dolors and Arjona-Torres, Cristina and Cañada-García, Javier E and García-Cobos, Silvia and Gracia-Ahufinger, Irene and Ortega-Portas, Cristina and Esteban, Jaime and Soto, Sara M and Cisneros, José Miguel and Lepe, José Antonio},
title = {Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes : a multicentre study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag034}
}
EUVIMED